ADMA Biologics Inc $ADMA Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 2,188.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,141,106 shares of the biotechnology company’s stock after buying an additional 1,091,241 shares during the quarter. BNP Paribas Financial Markets’ holdings in ADMA Biologics were worth $20,814,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Future Fund LLC boosted its stake in shares of ADMA Biologics by 52.0% during the fourth quarter. Future Fund LLC now owns 97,432 shares of the biotechnology company’s stock worth $1,777,000 after buying an additional 33,312 shares during the period. Geode Capital Management LLC raised its holdings in ADMA Biologics by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 5,830,941 shares of the biotechnology company’s stock valued at $106,374,000 after acquiring an additional 17,203 shares during the last quarter. Royce & Associates LP grew its stake in shares of ADMA Biologics by 32.4% during the 4th quarter. Royce & Associates LP now owns 1,234,467 shares of the biotechnology company’s stock valued at $22,517,000 after buying an additional 302,399 shares during the period. Bleakley Financial Group LLC lifted its holdings in shares of ADMA Biologics by 381.1% during the 4th quarter. Bleakley Financial Group LLC now owns 66,354 shares of the biotechnology company’s stock valued at $1,210,000 after acquiring an additional 52,562 shares in the last quarter. Finally, Clearstead Advisors LLC increased its stake in ADMA Biologics by 252.3% during the 4th quarter. Clearstead Advisors LLC now owns 7,827 shares of the biotechnology company’s stock worth $143,000 after buying an additional 5,605 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on ADMA. Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. Canaccord Genuity Group dropped their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Mizuho decreased their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.00.

Insider Buying and Selling

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This represents a 2.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman acquired 12,500 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the transaction, the director owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 3.90% of the stock is currently owned by corporate insiders.

ADMA Biologics Price Performance

ADMA stock opened at $7.97 on Friday. The company’s 50-day moving average price is $9.25 and its two-hundred day moving average price is $14.43. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $22.37. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The firm has a market cap of $1.85 billion, a P/E ratio of 11.72 and a beta of 0.72.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm’s quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company posted $0.11 EPS. On average, analysts anticipate that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.